Oncolytic adenovirus therapy as an adjuvant treatment for localised prostate cancer.

Published: 08-01-2013
Last updated: 15-05-2024

The main objective is to evaluate the safety and tolerability of Ad[I/PPT-E1A] as an adjuvant treatment for localised prostate cancer before radical prostatectomy. A secondary objective is to explore the histopathological and immunological effects...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Reproductive neoplasms male malignant and unspecified
Study type	Interventional

Summary

ID

NL-OMON43563

Source
ToetsingOnline

Brief title
Oncolytic adenovirus therapy in PCa

Condition

- Reproductive neoplasms male malignant and unspecified
- Prostatic disorders (excl infections and inflammations)

Synonym
prostate cancer, Prostate carcinoma

Research involving
Human

Sponsors and support

Primary sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam
Source(s) of monetary or material Support: Ministerie van OC&W

Intervention

Keyword: Adjuvant treatment, Localised prostate cancer, Oncolytic adenovirus therapy, Radical prostatectomy

Outcome measures

Primary outcome

The main study parameter is dose-limiting toxicity between 1x10E11 and 5x10E12

Virus Particles Ad[I/PPT-E1A], defined as any irreversible grade 3 or 4

toxicity.

Secondary outcome

Secondary study parameters are histopathological changes with respect to

necrosis and inflammatory features, immunological changes with respect to the

systemic and local innate and adaptive immune system profile, and the presence

of tumour-specific and adenovirus-specific T

cells in blood and the prostate before, during and after Ad[I/PPT-E1A]

oncolytic adenovirus therapy.

Study description

Background summary

Curative therapies for prostate cancer, like radical prostatectomy, often fail due to the recurrence of the disease that can be treated by palliative treatment only. The efficacy of surgery may be increased by adjuvant therapy aimed at the reduction of the amount of malignant tissue prior to surgery. Oncolytic adenoviruses that selectively kill cells of interest have shown promising results in patients with prostate cancer who failed radiotherapy and as an adjuvant to radiotherapy for localized disease. Even long term effects were observed, which most likely can be
explained by the induction of anti-tumour immunity.

Study objective

The main objective is to evaluate the safety and tolerability of Ad[I/PPT-E1A] as an adjuvant treatment for localised prostate cancer before radical prostatectomy. A secondary objective is to explore the histopathological and immunological effects induced by Ad[I/PPT-E1A] to get more insight in the mechanism of action of oncolytic adenovirus therapy.

Study design

Exploratory Phase I dose-escalating study to assess the safety and tolerability of Ad[I/PPT-E1A].

Intervention

Ad[I/PPT-E1A] will be administered 3 weeks prior to radical prostatectomy at 1x10E11, 1x10E12 or 5x10E12 Virus Particles by intraprostatic injection under guidance of transrectal ultrasound in 4 equal deposits with a total volume of 1 ml.

Study burden and risks

The burden associated with participation in this trial involves a single intraprostatic virus injection in 4 deposits 3 weeks prior to the radical prostatectomy and blood and urine collection at regular intervals from 4 weeks prior to surgery till 12 months after surgery. The risks for the patient associated with local administration of an oncolytic adenovirus at the proposed dosages are considered negligible. There are no clinical data for Ad[I/PPT-E1A] available yet and therefore a potential benefit for the patients may not be expected.

Contacts

Public
Erasmus MC, Universitair Medisch Centrum Rotterdam

Wytemaweg 80
Rotterdam 3015 CN
NL
Scientific
Erasmus MC, Universitair Medisch Centrum Rotterdam

Wytemaweg 80
Rotterdam 3015 CN
NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

1. Men * 18 years, scheduled to undergo radical prostatectomy in Erasmus MC
2. Histologically proven adenocarcinoma of the prostate
3. Clinical Stage T1b-T2, Nx-N0, M0 disease
4. Life expectancy > 10 years according to the European Association of Urology guidelines 2009
5. Written informed consent
6. Haematology:
- Absolute neutrophil count ANC * 1.5 x 10E9 /L
- Lymphocyte counts * 0.8 x 10E9/L
- Platelets * 100 x 10E9 /L
- Haemoglobin * 6.2 mmol/L
7. Chemistry:
- Aspartate aminotransferase (AST) * 2.5 x ULN
- Alanine aminotransferase (ALT) * 2.5 x ULN
- Creatinin * 1.5 x ULN
- Total bilirubin * 1.5 x ULN
8. Living within one hour travel distance of the hospital
9. Green light from anaesthesist, fit to undergo RP

Exclusion criteria

1. Prior androgen ablation hormonal therapy (except treatment with finasteride - if discontinued >
3 months prior to inclusion in current protocol)
2. Prior prostatic surgical procedure during which tissue was resected, except biopsies.
3. Continuous daily use of oral prednisone, oral dexamethasone, or other systemic corticosteroids for more than 14 days within 3 months prior to screening (inhaled, nasal and

local steroids are allowed (e.g. joint injection)
4. Concurrent treatment with immunosuppressive drugs (Imuran, cyclophosphamide, etc.).
5. Patients with uncontrolled infections, including uncontrolled infections of the urinary tract (defined as viral, bacterial or fungal infections requiring specific therapy)
6. Patients known to be HIV-positive or having another severe immunodeficiency
7. Prostatitis during the past 12 months
8. Any condition which, in the opinion of the investigator, would prevent full and safe participation in this trial, or would interfere with the evaluation of the trial endpoints

Study design

Design

Study type: Interventional

Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	21-10-2013
Enrollment:	18
Type:	Actual

Ethics review

Approved WMO Date:	08-01-2013
Application type:	First submission
Review commission:	CCMO: Centrale Commissie Mensgebonden Onderzoek (Den Haag)
Approved WMO Date:	12-03-2013
Application type:	First submission
Review commission:	CCMO: Centrale Commissie Mensgebonden Onderzoek (Den Haag)

Approved WMO Date:	28-08-2014
Application type:	Amendment
Review commission:	CCMO: Centrale Commissie Mensgebonden Onderzoek (Den Haag)
Approved WMO Date:	29-08-2014
Application type:	Amendment
Review commission:	CCMO: Centrale Commissie Mensgebonden Onderzoek (Den Haag)
Approved WMO Date:	07-10-2016
Application type:	Amendment
Review commission:	CCMO: Centrale Commissie Mensgebonden Onderzoek (Den Haag)
Approved WMO Date:	25-10-2016
Application type:	Amendment
Review commission:	CCMO: Centrale Commissie Mensgebonden Onderzoek (Den Haag)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

ID: 24928
Source: Nationaal Trial Register
Title:

In other registers

Register	ID
EudraCT	EUCTR2012-000853-30-NL
CCMO	NL39923.000.12

Register	ID
OMON	NL-OMON24928